Direct‐acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|270-9139|4|1298-1303

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.270-9139, Iss.4, 2015-10, pp. : 1298-1303

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Direct‐acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs

By  

HEPATOLOGY, Vol. 62, Iss. 4, 2015-10 ,pp. : 1298-1303

John Wiley & Sons Inc

Access to resources Recommend Favorite

The efficacy and safety of direct acting antiviral treatment and clinical significance of drug–drug interactions in elderly patients with chronic hepatitis C virus infection

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 44, Iss. 8, 2016-10 ,pp. : 856-865

John Wiley & Sons Inc

Access to resources Recommend Favorite

The clinical significance of drug–drug interactions in the era of direct‐acting anti‐viral agents against chronic hepatitis C

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 11-12, 2013-12 ,pp. : 1365-1372

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of hepatitis C virus infection with direct‐acting antiviral agents: 100% cure?

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. S1, 2018-02 ,pp. : 7-13

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reply to direct‐acting antiviral drugs and hepatitis C virus: A therapeutic revolution?

By  

CANCER, Vol. 121, Iss. 23, 2015-12 ,pp. : 4269-4270

John Wiley & Sons Inc

Access to resources Recommend Favorite